Daniel N. Swisher, Jr
2014 - Sunesis Pharmaceuticals
In 2014, Daniel N. Swisher, Jr earned a total compensation of $2.4M as CEO and President at Sunesis Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $202,000 |
|---|---|
| Option Awards | $1,736,160 |
| Salary | $488,094 |
| Other | $3,466 |
| Total | $2,429,720 |
Swisher received $1.7M in option awards, accounting for 71% of the total pay in 2014.
Swisher also received $202K in non-equity incentive plan, $488.1K in salary and $3.5K in other compensation.
Rankings
In 2014, Daniel N. Swisher, Jr's compensation ranked 3,760th out of 13,032 executives tracked by ExecPay. In other words, Swisher earned more than 71.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,760 out of 13,032 | 71st |
Division Manufacturing | 1,325 out of 4,965 | 73rd |
Major group Chemicals And Allied Products | 430 out of 1,690 | 75th |
Industry group Drugs | 334 out of 1,369 | 76th |
Industry Pharmaceutical Preparations | 269 out of 1,042 | 74th |
Source: SEC filing on April 20, 2017.
Swisher's colleagues
We found one more compensation record of an executive who worked with Daniel N. Swisher, Jr at Sunesis Pharmaceuticals in 2014.
2014
Eric Bjerkholt
Sunesis Pharmaceuticals
Chief Financial Officer
News
Jazz Pharmaceuticals CEO Bruce Cozadd's 2021 pay jumps 25% to $16M
June 10, 2022
Jazz Pharmaceuticals CEO Bruce Cozadd's 2020 pay slips 15% to $13M
June 11, 2021
Jazz Pharmaceuticals CEO Bruce Cozadd's 2019 pay jumps 29% to $15M
June 12, 2020
Jazz Pharmaceuticals CEO Bruce Cozadd's 2018 pay rises 11% to $11M
June 14, 2019